Details

Project TitleCOMMON hTERT PROMOTER MUTATIONS REPRESENT A NOVEL THERAPEUTIC TARGET (14050)
Track Code14050
Short Description
Abstract

COMMON hTERT PROMOTER MUTATIONS REPRESENT A NOVEL THERAPEUTIC TARGET (14050)

    

     

Features and Benefits Summary

  • Potential new target for anticancer therapeutic
  • Furthered understanding of promoter sequence regulation through g-quadraplex            oligonucleotides
  • Proven growth inhibition of cancer cells

 *This Technology is available for licensing, further development, or industrial partnering*

    

Market Opportunities

This technology offers the possibility of being developed into an anticancer therapeutic. Tests showed that in cancer cell lies with one or more telomerase reverse transcriptase (TERT) mutations can be inhibited via quadraplex stabilizing drugs or oligonucleotides with the wild type human TERT (hHERT). Therefore, these oligonucleotides could be developed into an effective cancer treatment option because these TERT mutations are very common in malignant melanomas and glioblastomas. hTERT is also overexpressed in a majority of other cancers so it is a viable target for controlling cancer growth and proliferation. Besides only serving as a therapeutic, the method by which these oligonucleotides interact with the mutations could serve as a biomarker for cancer. This could be developed into an imaging and early detection procedure to increase a patient’s chance of survival.

       

Technology   

 hTERT is a subunit of telomerase which is an important enzyme in cellular proliferation. In many human cancers, hTERT promoter is mutated in one or more of four locations. These locations form quadraplex DNA structures and this provides a possible target for g-quadraplex oligonucleotides and other drugs that stabilize these formations and prevent hTERT overexpression. By preventing overexpression of hTERT, cell proliferation decreased and this could control tumor growth and metastasis. It was shown that in normal, wild type hTERT cell lines, these oligonucleotides did inhibit cell growth, but to a very minimal extent. Therefore, these compounds are specific and selective and could serve as an anticancer therapeutic.

             

Technology Status

  • IP Status: Patent pending
  • Fields of Use Available: All
  • Development Status: Fully developed

    

Researchers:

  • Dr. Donald Miller

  • Shelia Thomas

  • Alexandra Sokolova
 
TagsNone
 
Posted DateApr 13, 2017 2:51 PM